| 标题 |
The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment |
| 网址 | |
| DOI | |
| 其它 |
期刊:Kidney International 作者:Éric Rondeau; Marie Scully; Gema Ariceta; Tom Barbour; Spero Cataland; et al 出版日期:2020-03-06 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)